Prostate-specific membrane antigen (PSMA)-targeting radiotracers have gained popularity over the last years in the setting of prostate carcinoma diagnosis (Gallium-68 (68Ga) PSMA) and treatment (Lutetium-177 (177Lu) PSMA). This evidence concerns the gene FOLH1 and prostate carcinoma.